Novocure Ltd (NVCR) FinancialsNVCRNovocure Ltd

Evaluating the bottom line, NovoCure Limited maintains a gross margin of 77.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.75%, while the net margin is -8.53%. These profitability ratios, combined with a Return on Equity (ROE) of -43.22%, provide a clear picture of how effectively NVCR converts its operational activities into shareholder value.

In the context of the broader market, NVCR competes directly with industry leaders such as KMTS and ATEC. With a market capitalization of $1.73B, it holds a significant position in the sector. When comparing efficiency, NVCR's gross margin of 77.61% stands against KMTS's 56.50% and ATEC's 70.34%. Such benchmarking helps identify whether NovoCure Limited is trading at a premium or discount relative to its financial performance.

Novocure's gross margin is strong at 77.61% for Q2 2026, and the company has raised its full-year revenue guidance to $710 million-$725 million, reflecting robust growth in its tumor treatment sector.